75 related articles for article (PubMed ID: 16955560)
1. [The molecular genetic assessment of prognostic factors in carcioma of the prostate: a pilot study].
Dvorácková J; Uvírová M
Cesk Patol; 2006 Jul; 42(3):130-2. PubMed ID: 16955560
[TBL] [Abstract][Full Text] [Related]
2. A molecularly genetic determination of prognostic factors of the prostate cancer and their relationships to expression of protein p27kip1.
Dvorácková J; Uvírová M
Neoplasma; 2007; 54(2):149-54. PubMed ID: 17319789
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer.
Tsuchiya N; Slezak JM; Lieber MM; Bergstralh EJ; Jenkins RB
Genes Chromosomes Cancer; 2002 Aug; 34(4):363-71. PubMed ID: 12112525
[TBL] [Abstract][Full Text] [Related]
4. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.
Jenkins RB; Qian J; Lieber MM; Bostwick DG
Cancer Res; 1997 Feb; 57(3):524-31. PubMed ID: 9012485
[TBL] [Abstract][Full Text] [Related]
5. Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients.
Sato H; Minei S; Hachiya T; Yoshida T; Takimoto Y
Int J Urol; 2006 Jun; 13(6):761-6. PubMed ID: 16834657
[TBL] [Abstract][Full Text] [Related]
6. 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy.
Fromont G; Godet J; Peyret A; Irani J; Celhay O; Rozet F; Cathelineau X; Cussenot O
Hum Pathol; 2013 Aug; 44(8):1617-23. PubMed ID: 23574779
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between chromosome 8 alterations and Gleason score in prostatic adenocarcinoma].
Zeng X; Wu SF; Xu Q; Xiao Y; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):523-8. PubMed ID: 17134545
[TBL] [Abstract][Full Text] [Related]
8. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
[TBL] [Abstract][Full Text] [Related]
9. Assessment of aberrations on chromosome 8 in prostatic atrophy.
Yildiz-Sezer S; Verdorfer I; Schäfer G; Rogatsch H; Bartsch G; Mikuz G
BJU Int; 2006 Jul; 98(1):184-8. PubMed ID: 16831166
[TBL] [Abstract][Full Text] [Related]
10. Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization.
Qian J; Jenkins RB; Bostwick DG
Mod Pathol; 1997 Nov; 10(11):1113-9. PubMed ID: 9388062
[TBL] [Abstract][Full Text] [Related]
11. Genetic profile identification in clinically localized prostate carcinoma.
Gallucci M; Merola R; Leonardo C; De Carli P; Farsetti A; Sentinelli S; Sperduti I; Mottolese M; Carlini P; Vico E; Simone G; Cianciulli A
Urol Oncol; 2009; 27(5):502-8. PubMed ID: 18534873
[TBL] [Abstract][Full Text] [Related]
12. The role of chromosome 8p22 deletion for predicting disease progression and pathological staging in prostate cancer.
Matsuyama H; Pan Y; Oba K; Yoshihiro S; Matsuda K; Hägarth L; Kudren D; Naito K; Bergerheim US; Ekman P
Aktuelle Urol; 2003 Jul; 34(4):247-9. PubMed ID: 14566675
[TBL] [Abstract][Full Text] [Related]
13. Relations of the c-myc gene and chromosome 8 in non-small cell lung cancer: analysis by fluorescence in situ hybridization.
Kubokura H; Tenjin T; Akiyama H; Koizumi K; Nishimura H; Yamamoto M; Tanaka S
Ann Thorac Cardiovasc Surg; 2001 Aug; 7(4):197-203. PubMed ID: 11578259
[TBL] [Abstract][Full Text] [Related]
14. Deletions on chromosome 8p22 may predict disease progression as well as pathological staging in prostate cancer.
Matsuyama H; Pan Y; Oba K; Yoshihiro S; Matsuda K; Hägarth L; Kudren D; Naito K; Bergerheim US; Ekman P
Clin Cancer Res; 2001 Oct; 7(10):3139-43. PubMed ID: 11595707
[TBL] [Abstract][Full Text] [Related]
15. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
Wang ZR; Liu W; Smith ST; Parrish RS; Young SR
Exp Mol Pathol; 1999 Jun; 66(2):140-8. PubMed ID: 10409442
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma.
Sato K; Qian J; Slezak JM; Lieber MM; Bostwick DG; Bergstralh EJ; Jenkins RB
J Natl Cancer Inst; 1999 Sep; 91(18):1574-80. PubMed ID: 10491435
[TBL] [Abstract][Full Text] [Related]
17. Deletion mapping of chromosome 8p in prostate cancer by fluorescence in situ hybridization.
Matsuyama H; Pan Y; Skoog L; Tribukait B; Naito K; Ekman P; Lichter P; Bergerheim US
Oncogene; 1994 Oct; 9(10):3071-6. PubMed ID: 8084616
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic profiles as additional markers to pathological features in clinically localized prostate carcinoma.
Gallucci M; Merola R; Farsetti A; Orlandi G; Sentinelli S; De Carli P; Leonardo C; Carlini P; Guadagni F; Sperduti I; Cianciulli AM
Cancer Lett; 2006 Jun; 237(1):76-82. PubMed ID: 16002207
[TBL] [Abstract][Full Text] [Related]
19. Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer.
Macoska JA; Trybus TM; Sakr WA; Wolf MC; Benson PD; Powell IJ; Pontes JE
Cancer Res; 1994 Jul; 54(14):3824-30. PubMed ID: 8033102
[TBL] [Abstract][Full Text] [Related]
20. Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients.
Ribeiro FR; Henrique R; Martins AT; Jerónimo C; Teixeira MR
Eur Urol; 2007 Jul; 52(1):116-25. PubMed ID: 17070983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
